QuidelOrtho Corporation (QDEL)
| Market Cap | 887.85M -60.9% |
| Revenue (ttm) | 2.66B -3.9% |
| Net Income | -1.21B |
| EPS | -17.81 |
| Shares Out | 68.19M |
| PE Ratio | n/a |
| Forward PE | 6.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,410,972 |
| Open | 13.15 |
| Previous Close | 13.07 |
| Day's Range | 12.86 - 13.28 |
| 52-Week Range | 9.92 - 35.58 |
| Beta | 0.74 |
| Analysts | Hold |
| Price Target | 18.63 (+43.09%) |
| Earnings Date | May 5, 2026 |
About QDEL
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or... [Read more]
Financial Performance
In 2025, QuidelOrtho's revenue was $2.73 billion, a decrease of -1.89% compared to the previous year's $2.78 billion. Losses were -$1.13 billion, -44.84% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for QDEL stock is "Hold." The 12-month stock price target is $18.63, which is an increase of 43.09% from the latest price.
News
When Blood Compatibility Becomes a Pregnancy Risk
SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic dis...
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its...
Hantavirus outbreak: these 3 stocks are poised to rip higher
The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed ...
QuidelOrtho price target lowered to $11 from $15 at JPMorgan
JPMorgan lowered the firm’s price target on QuidelOrtho (QDEL) to $11 from $15 and keeps an Underweight rating on the shares post the Q1 report. The firm cites weak respiratory…
QuidelOrtho price target lowered to $12 from $17 at UBS
UBS analyst Lu Li lowered the firm’s price target on QuidelOrtho (QDEL) to $12 from $17 and keeps a Neutral rating on the shares. The firm updated its model and…
QuidelOrtho downgraded to Hold from Buy at Jefferies
Jefferies analyst Tycho Peterson downgraded QuidelOrtho (QDEL) to Hold from Buy with a price target of $12.50, down from $35. The company reported a “disappointing” Q1 and provided a 2026…
QuidelOrtho price target lowered to $13 from $30 at Citi
Citi lowered the firm’s price target on QuidelOrtho (QDEL) to $13 from $30 and keeps a Neutral rating on the shares.
QuidelOrtho Earnings Call Transcript: Q1 2026
Q1 2026 results were impacted by a weak respiratory season and China headwinds, leading to lower revenue and margins, but core businesses and new product launches remain strong. Full-year guidance was lowered, with margin expansion and cash flow improvement expected in the second half.
QuidelOrtho Earnings release: Q1 2026
QuidelOrtho released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
QuidelOrtho Slides: Q1 2026
QuidelOrtho has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
QuidelOrtho Quarterly report: Q1 2026
QuidelOrtho has published its Q1 2026 quarterly earnings report on May 5, 2026.
QuidelOrtho reports adjusted Q1 EPS (4c), consensus 42c
Reports Q1 revenue $619.8M, consensus $659.17M. “Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business d...
QuidelOrtho sees FY26 adjusted EPS $1.80-$2.00, consensus $2.16
Previous view was $2.00-$2.42. Sees FY26 revenue $2.7B-$2.75B vs. previous view $2.7B-$2.9B, consensus $2.75B.
QuidelOrtho Reports First Quarter 2026 Financial Results
― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Compan...
QuidelOrtho Proxy statement: Proxy filing
QuidelOrtho filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
QuidelOrtho Proxy statement: Proxy filing
QuidelOrtho filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Understanding and Addressing Syphilis Trends - and What's Being Missed
SAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving sy...
TTP Group announces sale of LEX Diagnostics to QuidelOrtho
TTP announced the acquisition by QuidelOrtho (QDEL) Corporation of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics origi...
TTP Group Announces the Sale of LEX Diagnostics
CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based mole...
QuidelOrtho completes acquisition of LEX Diagnostics
QuidelOrtho (QDEL) announced it has completed the acquisition of LEX Diagnostics for cash consideration of approximately $100M. The LEX VELO System received U.S. FDA 510(k) clearance and CLIA waiver i...
QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics – – Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately T...
QuidelOrtho falls 12% to $15.25 after Q1 revenue guidance misses estimates
16:24 EDT QuidelOrtho (QDEL) falls 12% to $15.25 after Q1 revenue guidance misses estimates
QuidelOrtho sees Q1 revenue $615M-$620M, consensus $679.59M
The company currently expects preliminary unaudited revenue, as reported, of $615M-$620M for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory ...
QuidelOrtho sees Q1 free cash flow ($70M)-($65M)
As discussed in the company’s fourth quarter and full-year 2025 conference call in February, the company expects free cash flow to be negative for the first half of 2026. The…
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenu...